All section Close
Image Credits: Adobe Firefly
Strategic Partnership: Torrent Pharma & Zydus Collaborate On Liver Disease Drug
Writer: Tanya Chaturvedi
As a dedicated content writer, I thrive on the art of storytelling through various media forms. My passion lies in creating engaging, informative and visually captivating content that resonates with audience across platforms.
India, 21 Nov 2023 10:48 AM GMT
Editor : Ankita Singh |
A literature lover who likes delving deeper into a wide range of societal issues and expresses her opinions about the same. Keeps looking for best-read recommendations while enjoying her coffee and tea.
Creatives : Tanya Chaturvedi
As a dedicated content writer, I thrive on the art of storytelling through various media forms. My passion lies in creating engaging, informative and visually captivating content that resonates with audience across platforms.
Under the terms of the agreement, Torrent Pharmaceuticals secures semi-exclusive rights to co-market the product in India, branding it as Vorxar, according to a statement released by Torrent. Zydus Lifesciences, the original developer, had initially launched the drug under the brand names Lipaglyn and Bilypsa and will continue to market them.
In a strategic move, Torrent Pharmaceuticals has announced a significant licensing agreement with Zydus Lifesciences to co-market a groundbreaking medication for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). The collaborative effort aims to make Saroglitazar Mg more widely accessible throughout the nation.
Under the terms of the agreement, Torrent Pharmaceuticals secures semi-exclusive rights to co-market the product in India, branding it as Vorxar, according to a statement released by Torrent. Zydus Lifesciences, the original developer, had initially launched the drug under the brand names Lipaglyn and Bilypsa and will continue to market them.
Torrent Pharmaceuticals will provide upfront licensing fees and milestone payments to Zydus based on the achievement of pre-defined milestones, as outlined in the agreement.
Saroglitazar Magnesium, the only approved drug for NASH and NAFLD in India, is poised to play a pivotal role in managing and mitigating these prevalent and progressive liver disorders. Notably, there is currently no approved drug for the treatment of NASH and NAFLD anywhere else in the world.
Aman Mehta, Director of Torrent Pharmaceuticals, expressed confidence that the partnership would significantly enhance their gastroenterology franchise.
According to Sharvil Patel, Managing Director of Zydus Lifesciences, the collaboration with Torrent reflects their long-term vision of expanding the reach of this innovative drug. The partnership signifies a collective effort to address the pressing medical needs associated with liver disorders, providing a ray of hope for patients in India and potentially beyond.
This joint initiative is expected to have a positive impact on the treatment landscape for liver diseases, offering new possibilities for patients and advancing the pharmaceutical industry's commitment to addressing critical health challenges.
Also Read: Health Crisis in Delhi: Surge In Respiratory & Eye Issues
Must Reads
We are an independent and public-spirited digital media platform for Indian millennials. We report news and issues that matter as well as give you the opportunity to take action.
